PDF icon PDF herunterladen
Digestive Disease Interventions 2022; 06(03): 209-218
DOI: 10.1055/s-0042-1751238
Review Article

Update on Cholangiocarcinoma

David Irwin 
1   Division of Diagnostic Imaging, Department of Interventional Radiology, The University of Texas, MD Anderson Cancer Center, Houston, Texas
› Institutsangaben
Funding None.
› Weitere Informationen
Auch verfügbar aufeRef
   Lizenzen und Reprints
Preview

Abstract

Cholangiocarcinoma remains a challenge both in terms of diagnosis and treatment. Due to the lack of a useful screening test and often clinically silent early course, disease stage is often advanced at the time of diagnosis. Surgical resection remains the only potentially curative treatment option and recurrence rates are high; however, liver transplantation has recently resulted in promising outcomes in certain groups of patients with intrahepatic and perihilar cholangiocarcinoma. For patients in whom surgery is not an option, chemotherapy with gemcitabine and cisplatin is the first-line treatment. An array of locoregional management options exists, which includes transarterial embolization, hepatic arterial chemotherapy infusion, ablation, and radiation therapy. High-quality data from randomized controlled trials for these treatments remains limited, however, and additional study is needed.

Keywords

cholangiocarcinoma - embolization - ablation


Publikationsverlauf

Eingereicht: 18. März 2022

Angenommen: 25. Mai 2022

Artikel online veröffentlicht:
11. Juli 2022

© 2022. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA